Ipca appoints Hitesh Kumar Maheshwari as President – R&D (Formulations)
He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company
He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
NPPA also fixed retail price of 76 new drugs in the meeting dated 10th March 2021 to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.
Subscribe To Our Newsletter & Stay Updated